Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach

Authors:

Abstract
Summary: Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.
Funding Information
  • Cancer Research UK (C23338/A25722, C16731/A21200)
  • Wellcome Trust (209213/Z/17/Z)

This publication has 12 references indexed in Scilit: